The long-term morbidity of tendon disease in an increasingly active and ageing population represents a growing area of unmet clinical need. Tendon disorders commonly affect the lower limb, ranging from isolated tendon rupture to degenerative joint deformity. In the absence of valid animal models of chronic tendinopathy, traditional methods to isolate and identify crucial sub types involved in disease are limited by the heterogeneity of tendon cells, by their relative paucity in tissue and by the density of the surrounding collagen matrix. To overcome this, we have used next generation CITE-sequencing to combine surface proteomics with in-depth, unbiased gene expression analysis of single cells derived ex vivo from healthy and diseased tendon.
Introduction
Musculoskeletal disorders are responsible for the second largest number of years lived with disability worldwide (1) . The morbidity associated with tendon degeneration in an ageing, and increasingly active, population represents an escalating challenge to healthcare services. Tendinopathy affects up to third of the population, accounting for 30% of primary care consultations (2) (3) (4) . Tendon disorders commonly affect the lower limb and result in long term pain and disability.
These range from isolated tendon rupture (most commonly the Achilles tendon), to disease that drives complex foot deformity, such as adult acquired flat foot deformity (AAFD) affecting 2-3% of the adult population (5) (6) (7) .
Early research into patients with Marfan syndrome demonstrated that tendon cells are surrounded by peri-cellular matrix microfibrils formed by fibrillin chains and bound ancillary proteins (including versican, fibulin, matrix associated glycoproteins). They represent a mechanism for altering growth factor signalling (e.g. sequestering TGF-beta), controlling morphogenic gradients, and influencing cell interactions with the extracellular collagen matrix (8) (9) (10) . They may allow resident tenocytes to sample, respond and influence tendon structure and function (11) . The development of new therapies involves understanding how key subpopulations of tendon cells/fibroblasts are able to maintain a dense tendon extracellular matrix and importantly, how they survey and respond to events which threaten tissue integrity.
The bulk of tendon consists of dense collagen extracellular matrix and residing cells tend to be sparse (particularly in healthy tendon), heterogenous and auto-flourescent; so limiting previous techniques (e.g. flow cytometry) for studying cells of interest. Moreover the mechano-sensitivity of tendon cells risks confounding their interrogation in vitro including the associated changes in gene expression (12) .
It is currently not possible to define, isolate and target specific sub-populations of matrix producing tendon cells involved in human disease. Single cell RNA sequencing offers an unbiased, agnostic and sensitive inventory of the transcriptome of individual cells and allows characteristics of groups of cells based on shared and differential gene expression data (13) . This approach has been successfully used to characterise cell types is mouse tissue (14) (15) (16) (17) .
CITE-Seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing)
is a novel iteration of single cell sequencing that uses oligonucleotide barcodes conjugated to monoclonal antibodies to combine surface proteomics with single cell RNA/transcriptomic information. To our knowledge this is the first time CITE-Seq has been applied to healthy and diseased human tendon. We have identified multiple sub-populations of cells in human tendon, five of which show increased expression of COL1A genes. These include two groups that co-express microfibril genes, a group expressing genes associated with fibro-adipogenic progenitors (FAPs), a TPPP3/PRG4+ chondrogenic group and ITGA7+ Smooth Muscle-Mesenchymal Cells (SMMCs), previously described in mouse but not in human tendon (16, 17) . These findings support the presence of multiple specialised tendon cell sub-types and open new avenues to interrogate key cell pathways that underpin chronic tendon disease.
Methods

Collection of tissue tendon samples donated by patients
Tendon biopsies were collected from patients with informed donor consent under ethics from the Oxford Musculoskeletal Biobank (09/H0606/11) in compliance with National and Institutional ethical requirements. Only waste tissue that would otherwise have been disposed of was collected. Healthy tendon samples were obtained form patients undergoing tendon transfer procedures. These included patients undergoing hamstring (gracilis and semimembranosus) tendon reconstruction of knee anterior cruciate ligament; reconstruction of irreparable Achilles tendon rupture using flexor hallucis longus tendon; and tibialis posterior tendon transfer procedures to improve foot biomechanics. Diseased tendon samples were obtained from patients undergoing surgical exploration and debridement of intractable, chronic painful tendon disease. These included tendinopathic peroneus longus, the Achilles tendon and the extensor digitorum tendon associated with a painful fixed flexed deformity of the proximal interphalangeal joint ('Hammer toe').
Tendon sample digestion
Samples were immediately placed in 4℃ Iscove's Modified Dulbecco's Medium (IMDM) without antibiotics and without FCS. The tendons were rinsed in 1
x PBS, cut axially using a size 10 surgical scalpel into 1mm 3 pieces and incubated at 37℃ for 45 mins in LiberaseTM (Merck) and 10ul/ml DNAse I (Thermo Scientific™). Ham's F-12 media + 10% FCS was added and the digested tissue passed through a 100µm cell strainer. The cells suspension was centrifuged at 350g for 5 mins and re-suspended in 1ml of FCS:DMSO (9:1) freezing medium and immediately placed in -80℃ storage for future batch analysis.
CITE-seq
Digested healthy and diseased samples were defrosted, washed and resuspended in 100µl staining buffer (1 x PBS + 2% BSA + 0.01% Tween). As per the CITE-Seq protocol (https://citeseq.files.wordpress.com/2019/02/cite-seq_and_hashing_protocol_190213.pdf), cells were then incubated for 10 minutes at 4˚C in human Fc Blocking reagent (FcX, BioLegend). Cells were incubated at 4˚C for a further 30 minutes with 0.5µg of TotalSeq™-A (Biolegend) monoclonal anti-CD10, anti-CD105, anti-CD146, anti-CD26, anti-CD31, anti-CD34, anti-CD44, anti-CD45, anti-CD54, anti-CD55, anti-CD90, anti-CD95, anti-CD73, anti-CD9 and anti-CD140a antibodies (see Table S1 ). In addition each sample cell suspension was incubated with 0.5µg of the relevant cell hashing antibodies (Biolegend). The cells were then washed three times with staining buffer and re-suspended in 1 x PBS at 1000 cells/µl. The cells suspensions were filtered using a 100µm sieve. The final concentration, single cellularity and viability of the samples, was confirmed using a haemocytometer. Cells were loaded into the Chromium controller (10x-Genomics) chip following the standard protocol for the Chromium single cell 3' kit. A combined hashed cell concentration was used to obtain an expected number of captured cells between 5000-10000 cells. All subsequent steps were performed based on the CITE-Seq protocol (https://citeseq.files.wordpress.com/2019/02/cite-seq_and_hashing_protocol_190213.pdf). Libraries were pooled and sequenced across multiple Illumina HiSeq 4000 lanes to obtain a read depth of approximately 30,000 reads per cell for gene expression libraries.
The raw single-cell sequencing data was mapped and quantified with the 10x Genomics Inc. software package CellRanger (v2.1) and the GRCh38 reference genome. Using the table of unique molecular identifiers produced by Cell Ranger, we identified droplets that contained cells using the call of functional droplets generated by Cell Ranger. After cell containing droplets were identified, gene expression matrices were first filtered to remove cells with > 5% mitochondrial genes, < 200 or > 5000 genes, and > 25000 UMI. Downstream analysis of Cellranger matrices was carried out using R (3.6.0) and the Seurat package (v 3.0.2, satijalab.org/seurat).
After quality control filtering, data were normalised for RNA gene expression, hashed antibody (HTO) and surface antibody (ADT) expression level. Based on the HTO expression level, we were able to subsample cells from a particular donor tendon ( Figure S2 ). Normalised data from all healthy tendon cells were combined into one object and integrated with data from cells of diseased tendon. Variable genes were discovered using the SCtransform function with default parameters. (18) . Clustering was performed on the Integrated assay at a resolution of 0.5 with otherwise default parameters which yielded a total of 12 clusters, each composed of cells originating from both healthy and diseased samples across the study patients (19) .
Histology
Immunohistochemistry was performed on a Leica Bond™ system using the standard protocol F30. The sections were pre-treated using heat mediated antigen retrieval with citrate-based buffer (pH6, epitope retrieval solution 1) or EDTA based buffer (pH9, epitope retrieval solution 2) for 20 mins. The sections were then incubated with antibody for 30 mins at room temperature and detected using an HRP conjugated polymer system in which DAB was used as the chromogen. The 
Results
A single cell atlas of human tendon in health and disease
In order to characterise healthy and diseased human tendon cell subtypes, we performed scRNA-seq and CITE-seq integrated analysis of cells from eight healthy and eleven diseased tendon samples. Cells were incubated with one of eight surface hashing antibodies so that their sample of origin could be identified following sequencing in one of three lanes. After normalization and quality control of the transcriptome data, cells were selected based on high 'expression level' of their donor specific surface hashing antibody and low 'expression level' of the remaining hashing antibodies. In total, 11,948 cells with an average of 1,700 genes per cell were selected for ongoing analysis. Of these single cells, 6,411 were obtained immediately ex-vivo from digested healthy and diseased tendon and all subsequent data is derived from this group of cells. The remainder were cells from P1 culture of two healthy and one diseased tendon to allow comparison with ex-vivo single cell sequencing (Figure 1 
Multiple distinct tenocyte populations reside in human tendon
The five cell clusters that expressed tendon matrix COL1A1/2 were provisionally labelled Tenocyte A-E. In order to delineate these groups further, the expression of genes coding for the commonest matrix proteins found in human tendon (20) was compared across the five clusters ( Figure 3A , dot plot). The gene expression of any given COL1A+ cluster was also directly compared to the remaining four clusters to highlight any additional differences between clusters ( Figure 3B and Tenocyte E cells (CD26 + /CD90 low CD54 low CD10 neg ).
Stromal cell populations are dynamic in human tendon disease.
The Tenocyte A cluster predominantly contained cells from diseased tendon ( Figure   2A , S4). This cluster had a similar gene expression profile to Tenocyte B cells but expressed high levels of pro-inflammatory genes including CXCL1, CXCL6, CXCL8
and PTX3. Co-localisation plots shown in Figure 5A illustrate that within the Tenocyte A cluster, the the same cells that expressed CXCL1 co-expressed CXCL6 and CXCL8. This band of cells predominantly came from diseased tendon samples and very few were found to originate from healthy tendon ( Figure 5B Figure 6C ) and these cells were distinct from SMA+CD31+ endothelium ( Figure 6A,B) . ITGA7 stained cells tended to be situated near blood vessels in small clusters and occasionally formed shorter strings of cells ( Figure   6F ). Groups of cytokeratin 7 and periostin stained cells were found near the periphery of tendon samples or were clustered within the main substance ( Figure   6D , E). Some of these formed chains of cells but without the distinct morphology of PTX3 cells. A minority of cells stained positively for the secreted chemokine CXCL14 and a small group were positive for the intracellular Matrix gla protein ( Figure 6H ).
Discussion
In the absence of a valid in vivo model of chronic tendon disease, understanding those pathways responsible for tendinopathy has been hampered by conventional methods to isolate crucial cells of interest. In this study, we have combined unbiased single cell gene analysis with surface proteomics of ex vivo single cells and described five sub-populations of COL1A expressing human tendon cell (21) .
In order to highlight the differences between healthy and diseased tissue, samples of three anatomical sites (digital extensor, peroneal and Achilles tendons) were obtained from patients with exclusively end stage tendon disease that had failed to improve despite all non operative measures. To our knowledge this is the first time this approach has been applied to healthy and diseased human tendon.
Five cell clusters were found to express collagen matrix associated genes.
The inherent variability in gene expression resulting from technical differences across batches, between different donor individuals and different anatomical sites remains a major limitation of this study (31, 35) . Cell clusters were generated using unbiased analysis of differential gene expression but did not include analysis of matrix protein production. It remains possible that the tendon sub-populations identified above represent confounding transcriptomic variation within a single tendon population and/or that a number of cell types failed to survive the digestion process. Hakimi et al. investigated the extracellular proteome of human tendon by comparing healthy and torn shoulder (supraspinatus) tissue (20) . As well as identifying a group of proteins up-regulated in diseased tissue, their work serves to provide a catalogue of the most abundant matrix proteins in healthy and diseased human tendon. The gene set of these proteins were therefore used to analyse our data and mapped onto the five discrete COL1A+ clusters, strengthening the initial unbiased observation of five distinct groups ( Figure 3A) . Tenocyte A and Tenocyte B both expressed high levels of COL1A1/2 and microfibril genes including fibrillin 1 (FBN1), versican (VCAN), decorin (DCN), elastin microfibril interfacer 1 (EMILIN1) and microfibril-associated glycoprotein 2/ microfibril associated protein 5 (MFAP5). Together these form microfibril chains that have previously been shown to surround a string of tendon resident cells, linking them to the much denser extracellular collagen matrix (11, 22, 23) . Histological analysis of human tendon revealed long thin chains of PTX3 positively stained cells that may represent these micro-fibril associated cells ( Figure 6C ). The observation that microfibrils bind growth factors such as TGFβ and BMP has led to the hypothesis that they play a role in allowing the relatively few resident tendon cells to sample and respond to changes in the surrounding type I collagen matrix (8, 9, 11) .
Activation of TGFβ signalling involves release of the growth factor from its latent microfibril complex. A number of mechanisms have been described including mechano-transduction, enzymatic degradation, reactive oxygen species and low pH (24) . Both LTBP1 and LTBP2 expression was greatest in Tenocyte A and Tenocyte B compared to the other matrix cell clusters. LTBP2 is the only isoform that does not bind to latent TGFβ but rather binds to preformed fibres of fibrillin-1 (25) . It competes with LTBP1 for the same binding site and so may provide an additional way in which TGFβ cell signalling is activated in tendon cells by releasing LTBP1 from microfibrils (26) .
Higher levels of COL4A1, KRT7, POSTN, TAGLN, THBS1, TIMP3, IGFBP5/7
and COL5A were seen in Tenocyte B compared to Tenocyte A. It is not clear if Tenocyte B and Tenocyte A represent two separate populations of tendon cells. One of the advantages of CITE-Seq is that it also uses oligo-nucleotide conjugated monoclonal antibodies to recognise cell surface proteins. In this case, Tenocyte B cells were found to have greater levels of surface CD105 and CD146 compared to Tenocyte A cells which were CD10+CD26+CD54+. It remains possible that they share a common progenitor and have developed to perform overlapping roles in response to tissue damage. Alternatively, since Tenocyte A is predominantly composed of diseased tendon cells and virtually all the cells that express chemokine genes CXCL1, CXCL6 and the cytokine CXCL8 (IL-8) are from diseased tendon samples, it may be that Tenocyte A cells respond to ECM disruption by recruiting and converting other COL1A+ cells to increase their expression of reparative matrix genes.
In addition to CXCL1, CXCL6 and CXCL8, diseased tendon cells in Tenocyte A demonstrate increased expression of inflammatory genes PDPN (podoplanin), VCAM-1 (CD106) and CD248 ( Figure 5 ). These three were found to be upregulated in Achilles tendinopathic tissue compared to healthy control tendon (27, 28) . We found greatest expression of VCAM-1, CD248, PDPN on SCX+/microfibril associated cells from Tenocyte A. This further suggests that in the setting of chronic damage, tendon resident COL1A+ cells adopt a pro-inflammatory phenotype.
In keeping with previous studies, the predominant immune cell sub-types in tendon are monocytes and Tc cells (28) . Similarly, immunostaining of diseased human Achilles samples found reduced levels of IL33 compared to healthy or treated patient samples and this was associated with CD68+ macrophages on immuno-flourescence (29) . In our study, IL33 expression was predominantly found in clusters containing cells with endothelial gene markers and high surface CD31/ CD34, with little expression in CD68+ clusters or cells expressing collagen genes.
PTX3 was also found to be increased in diseased cells compared to healthy tendon cells in the Tenocyte A cluster ( Figure 5 ). It encodes a member of the pentraxin protein family and is induced by inflammatory cytokines. PTX3 has previously been found in endothelial cells and mononuclear phagocytes. In relation to tendon disease, one study found increased PTX3 in rat model of tendon responses to mechanical stress (30) but there is little prior data on its expression in human tendon disease.
In order to highlight the observed differences between healthy and diseased tendon, the diseased samples were restricted to extreme conditions in which there was end stage tendon disease that remained symptomatic despite all non operative therapies. Our observations are therefore unlikely to be relevant to earlier stages of disease. Furthermore, while there is no significant difference in the male to female distribution of samples in diseased versus healthy samples, diseased samples were obtained from a significantly older patient group (Figure 1 ). Age related changes in tendon cell gene expression have been found on bulk sequencing (31) and it is possible that this explains the observed differential gene expression between healthy and diseased cells. Finally, a more thorough histological analysis of these inflammatory mediators is required to appreciate their relevance in tendon pathophysiology. to Tenocyte E, cells in Tenocyte D exhibited greater expression of tendon collagen genes COL1A1/2, COL3A1; microfibril genes FBN1 and MFAP5; and chemoattractants CXCL2, CXCL14. Whereas, Tenocyte E cells expressed TPPP3 and PRG4 found in putative tendon stem cells that reside in the paratenon of mice patella tendon and respond to acute tendon injury by producing reparative matrix (17) . In our cohort, these cells co-expressed genes associated with cartilage formation including ASPN, COMP, PCOLCE2, FMOD, CILP, FN1 and PRELP and were largely found in clusters around disorganised matrix ( Figure 6 ). Further work is required to explore whether these differences represent a genuine phenotypic deviation in which reparative PRG4+ cells switch to produce a more cartilaginous matrix in the chronic setting; perhaps as a last ditch effort to maintain some structural integrity.
Smooth Muscle-Mesenchymal Cells (SMMCs) were defined in mouse muscle by Giordani et al. as a group of VCAM-cells that express ITGA7, RGS5 and MYL9 (16) . When mouse SMMCs were isolated, a myogenic subset were found to promote muscle growth, forming chimeric myotubes in culture with muscle satellite cells (MuSCs). We found a similar cluster of cells in both healthy and disease human tendon (Figure 2, 3) and theses tended to be situated around vessels ( Figure 6 ). To our knowledge this is the first demonstration of these cells in human tendon and, in keeping with their original description, they do not express endothelial markers found in pericytes (33) . Proteomic analysis revealed surface expression of CD90 and CD146 on these human cells ( Figure 5 ).
One explanation for the presence of SMMCs may be that tendon samples were taken close the myo-tendinous junction and so muscle tissue was inadvertently included. While this may be a possibility for the healthy hamstring tendon samples, even despite of careful dissection, the SMMCs cluster consisted of cells from all tendon samples including the majority taken well distal to the muscle insertion. The tendon-bone enthesis interface was also avoided and this is supported by the low expression of COL2A1 genes across all the clusters ( Figure   3A ). Interestingly, SCX positive 'tendon fibroblasts', similar to Tenocyte B and Tenocyte A, were found in mouse muscle devoid of tendon tissue by Giordani et al.
Further work could investigate whether these two seemingly out of place cells are the remnants of respective populations that once had a developmental role or if they still have an adult function, for example a co-ordinated structural response to injury of both muscle and tendon.
One previous study of human tendon used Fluidigm single cell analysis to identify a group of nestin+ putative tendon stem/progenitor cells. This was limited to 71 human tendon cells, all cultured to passage 1 and analysed using 46 gene transcripts. It identified three main cell clusters including a minority expressing increased levels of NES/CD31/CD146( (34) . In our data set of over 6,000 cells obtained immediately ex vivo from human tendon, NES (nestin) expression was predominantly found in endothelial cell cultures co-expressing PECAM-1, CD34 and surface CD34/CD31 (Figure 2,3 and S5 ). This fits with the published nestin+ immunostaining of human Achilles tendon that coincided with blood vessel endothelium. A small percentage of endothelial cells in our study co-expressed 
Figure 1. Patient donor demographics of healthy and disease tendon
Healthy tendon was obtained from patients who underwent tendon transfer procedures for reconstruction of knee anterior cruciate ligament (ACL), or ruptured Achilles tendon or to treat foot drop. Diseased tendon samples were restricted to patients who had chronic tendinopathy and medically intractable pain. Diseased tendon samples were from significantly older patients than healthy tendon (mean age 55 years v 39 years, p= 0.04). * Used for immuno-histochemistry. 
